Abingworth

R1 debuts with $77.5M to advance kidney disease treatment

R1 Therapeutics is debuting with $77.5 million aimed at advancing its first-in-class therapy for patients on dialysis with chronic kidney disease (CKD).

Will Maddox Mar 17, 2026 7:00am

Addition Tx does the math and emerges from stealth with $100M

Dec 17, 2025 7:45am

Antares and Rho Ophiuchi cloud complex in the Sagittarius constellation

Scorpion spinout Antares raises $177M for preclinical portfolio

Jun 10, 2025 10:07am

Gene therapy biotech secures $150M for eye disease candidates

Apr 2, 2025 7:30am

Myricx secures $114M series A to push ADCs into clinic

Jul 8, 2024 1:00am

Abingworth channels $356M into late-stage clinical programs

Oct 30, 2023 10:55am